Chemistry:BPC-157

From HandWiki
Short description: Peptide

BPC-157
Clinical data
Routes of
administration		IM, IV, IP (in animals), oral, subQ
Drug classpeptide
Legal status
Legal status
  • Not marketed
Pharmacokinetic data
Elimination half-life7.9–30 minutes (rat, IV and IM)[1]
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC62H98N16O22
Molar mass1419.556 g·mol−1
3D model (JSmol)

Gastric pentadecapeptide BPC-157 (also known as Body Protection Compound 157, bepecin, or PL 14736) is a synthetic fifteen amino acid oligopeptide derived from a protein found in human gastric juice. BPC-157 has been studied primarily in laboratory animals. BPC-157 is not approved by any drug regulatory agency for human use, and there is limited data regarding its effectiveness on humans.

The peptide has gained popularity among athletes and the general public for injury recovery, leading the World Anti-Doping Agency to ban it in 2022. Health authorities discourage its use due to insufficient human safety data, and some jurisdictions have restricted it as a prescription-only medicine despite it not being available through legitimate prescriptions. Additionally, because the compound promotes blood vessel formation (angiogenesis), there are theoretical concerns about potential cancer promotion that require further investigation.

The peptide was discovered during research on human gastric juice.[2] The amino acid sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val.[3] BPC-157 is stable at room temperature and bioavailable in rodent models when administered IM or IV.[1] The peptide demonstrates remarkable stability in human gastric juice, remaining intact for more than 24 hours, which supports its therapeutic effectiveness when administered orally.[4]

Pharmacology

Mechanism of action

BPC-157 works through several interconnected biological pathways that promote healing and tissue repair. Intuitively, the peptide acts analogous to a chemical messenger activating various repair mechanisms in the body.

Blood vessel formation and repair

The primary way BPC-157 promotes healing is by activating the VEGF receptor 2 (VEGFR2) pathway.[5] VEGF (Vascular Endothelial Growth Factor) is a protein that signals the body to create new blood vessels—a process called angiogenesis. Blood vessels function as the transportation network that delivers oxygen, nutrients, and repair materials to damaged tissues. Without adequate blood supply, injured tissues cannot heal properly.

When BPC-157 binds to VEGFR2 receptors on the surface of endothelial cells (the cells that line blood vessels), it triggers a cascade of events. The receptor becomes phosphorylated—meaning phosphate groups attach to it, activating it like flipping a switch. This activation then triggers the Akt-eNOS pathway, which increases production of nitric oxide (NO) in the blood vessel walls.[6] Nitric oxide causes blood vessels to dilate (widen), improving blood flow to injured areas and allowing more oxygen and healing nutrients to reach damaged tissues.

Cellular signaling and repair pathways

BPC-157 activates several other molecular pathways that work together to promote tissue repair.[7]

Focal adhesion kinase (FAK)-paxillin complexes are activated, which help cells migrate and attach to surfaces. This is crucial for wound healing because cells need to move into damaged areas and anchor themselves to begin rebuilding tissue. The peptide stimulates JAK-2 (Janus kinase 2), a protein that relays signals from outside the cell to the nucleus where genes are activated. This signaling pathway is involved in cell survival, growth, and immune responses—all essential for healing.

Early Growth Response gene 1 (Egr-1) is also activated. This gene acts like a master switch that turns on many other genes involved in cell growth, survival, and blood vessel formation. When Egr-1 is upregulated, it signals cells to grow and repair. The extracellular signal-regulated kinases (ERK1/2) pathway becomes activated as well. This pathway controls cell division and survival. When tissues are damaged, new cells must divide to replace dead or injured ones, and ERK1/2 activation promotes this cell multiplication.

Gene expression changes

BPC-157 is purported to work by changing which genes are expressed in cells, particularly in brain tissue after injury.[8] When genes are upregulated (increased), specific biological effects occur:

Vegfr2 upregulation produces more VEGF receptors, making cells more sensitive to growth signals and better able to form new blood vessels. Nos3 and Nos1 genes produce enzymes that make nitric oxide, which dilates blood vessels and improves blood flow. Akt1 promotes cell survival and prevents damaged cells from dying prematurely, giving them time to repair. Src helps cells communicate with each other and respond to growth signals. Kras is involved in cell growth and division—essential for replacing damaged cells. Foxo and Srf are transcription factors that regulate many genes involved in stress resistance, metabolism, and cell survival.

BPC-157 downregulates (decreases) certain genes that can be harmful during healing. Nos2 produces large amounts of nitric oxide during inflammation, which can damage tissues if overproduced. By reducing Nos2, BPC-157 may help control excessive inflammation. NF-κB (Nuclear Factor kappa B) is a major inflammation-promoting factor. While some inflammation is necessary for healing, excessive amounts can cause additional tissue damage. By downregulating Nfkb, BPC-157 may reduce harmful inflammatory responses.

Endothelial function

BPC-157 modulates Src and caveolin-1 (Cav-1) phosphorylation.[6] Caveolin-1 is a protein found in small pockets (caveolae) on the cell membrane. When BPC-157 affects these proteins, it changes how VEGFR2 receptors are internalized into cells and how endothelial nitric oxide synthase (eNOS) is activated. The result is sustained production of nitric oxide, which keeps blood vessels dilated and ensures continuous blood flow to healing tissues.

Overall effect

These mechanisms work together to create an optimal environment for tissue repair. BPC-157 increases blood flow to damaged areas, promotes new blood vessel formation, encourages cell survival and growth, facilitates cell migration to injury sites, and balances inflammatory responses to prevent excessive tissue damage while still allowing necessary healing inflammation.

Dosage and administration

In research settings, typical human dosages of BPC-157 range from 200 to 500 micrograms (μg) daily. Animal studies commonly employ doses of 6–50 micrograms per kilogram (μg/kg) body weight administered once or twice daily. The peptide can be administered through various routes including intraperitoneal (IP) injection, subcutaneous (SC) injection, intramuscular (IM) injection, intravenous (IV) infusion, or oral administration.[1] The half-life following IM or IV administration is less than 30 minutes, indicating rapid clearance from circulation.[1]

Both 100 μg/kg/day repeated IM dosing and once-time 500 μg/kg IM dosing are well-tolerated by rats.[1] A 2025 pilot study in humans evaluated IV infusion of BPC-157 at doses of 10 mg followed by 20 mg the next day in two adults, demonstrating no adverse effects on cardiac, hepatic, renal, thyroid, or glucose biomarkers, with the peptide being well-tolerated.[9]

Research

Pre-clinical research has indicated that BPC-157 may have cytoprotective, neuroprotective, and anti-inflammatory effects, and may also accelerate tissue and organ healing.[8][10][11][4][12][13]

Vascular and organ protection

Research has demonstrated that BPC-157 can counteract vessel occlusion syndromes by rapidly activating collateral blood vessel pathways, effectively bypassing occluded or damaged vessels.[14] Studies in rat models have shown effectiveness in treating complications from occlusion of major vessels including the superior mesenteric artery and vein, as well as therapeutic effects in models of glaucoma induced by episcleral vein cauterization.[15]

Musculoskeletal and neurological applications

BPC-157 has demonstrated beneficial effects in various musculoskeletal injury models, including tendon ruptures, ligament tears, muscle detachment, and bone healing.[16] The peptide has shown neuroprotective properties in models of traumatic brain injury, spinal cord compression, and peripheral nerve transection.[17] Animal studies have documented effects on neurotransmitter systems, particularly serotonergic and dopaminergic pathways.[7]

This substance is sometimes used in functional medicine despite not being approved by any drug regulatory agency.[7] The compound promotes angiogenesis and as a result has some concerns over cancer promotion.[18]

As of 2022, the peptide has been banned by the World Anti-Doping Agency under the S0 category of non-exempt substances.[19][20]

BPC-157 has been widely used both by athletes and among the general public, mainly for recovery from injury or stimulating healing in chronic conditions,[21][22][16][23] but there is as yet only very limited human trial data on efficacy and only a few preliminary safety studies,[24][25][26] so use of BPC-157 is discouraged by health authorities and it has been controlled as a prescription medicine in several jurisdictions such as New Zealand and Australia, despite not actually being available for prescription.[27][28]

Detection

BPC-157 is detected in urine using a weak cation exchange solid phase extraction and was found to be stable in urine for 4 days.[29]

See also

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 He, Lei; Feng, Donglin; Guo, Hui; Zhou, Yueyuan; Li, Zhaozhao; Zhang, Kuo; Zhang, Wangqian; Wang, Shuning et al. (2022-12-14). "Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs". Frontiers in Pharmacology (Frontiers Media SA) 13. doi:10.3389/fphar.2022.1026182. ISSN 1663-9812. PMID 36588717. 
  2. ↑ Chang, Chung-Hsun; Tsai, Wen-Chung; Lin, Miao-Sui; Hsu, Ya-Hui; Pang, Jong-Hwei Su (2011). "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration". Journal of Applied Physiology (American Physiological Society) 110 (3): 774–780. doi:10.1152/japplphysiol.00945.2010. ISSN 8750-7587. PMID 21030672. 
  3. ↑ "Pentadecapeptide BPC 157 attenuates disturbances induced by neuroleptics: the effect on catalepsy and gastric ulcers in mice and rats". European Journal of Pharmacology 379 (1): 19–31. August 1999. doi:10.1016/S0014-2999(99)00486-0. PMID 10499368. 
  4. ↑ 4.0 4.1 "Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract". Current Pharmaceutical Design 17 (16): 1612–32. 2011. doi:10.2174/138161211796196954. PMID 21548867. 
  5. ↑ "Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation". Journal of Molecular Medicine 95 (3): 323–333. March 2017. doi:10.1007/s00109-016-1488-y. PMID 27847966. 
  6. ↑ 6.0 6.1 "Modulatory effects of BPC 157 on vasomotor tone and the Src-Cav-1-eNOS signaling pathway in rats". Scientific Reports 10 (1): 17078. October 2020. doi:10.1038/s41598-020-74022-y. PMID 33046803. 
  7. ↑ 7.0 7.1 7.2 "Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications". Current Neuropharmacology 14 (8): 857–865. 2016. doi:10.2174/1570159x13666160502153022. PMID 27138887. 
  8. ↑ 8.0 8.1 "Pentadecapeptide BPC 157 and the central nervous system". Neural Regeneration Research 17 (3): 482–487. March 2022. doi:10.4103/1673-5374.320969. PMID 34380875. 
  9. ↑ "Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study". Alternative Therapies in Health and Medicine. September 2025. PMID 40131143. 
  10. ↑ "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves possible tendon outgrowth, cell survival, and cell migration". Journal of Applied Physiology 110 (3): 774–780. October 28, 2010. doi:10.1152/japplphysiol.00945.2010. PMID 21030672. https://journals.physiology.org/doi/pdf/10.1152/japplphysiol.00945.2010. 
  11. ↑ "Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth". Journal of Orthopaedic Research 21 (6): 976–983. 2003. doi:10.1016/S0736-0266(03)00110-4. PMID 14554208. https://www.sciencedirect.com/science/article/abs/pii/S0736026603001104. 
  12. ↑ "Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response". Inflammopharmacology 14 (5–6): 214–221. December 2006. doi:10.1007/s10787-006-1531-7. PMID 17186181. 
  13. ↑ "Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat". Journal of Orthopaedic Research 28 (9): 1155–1161. September 2010. doi:10.1002/jor.21107. PMID 20225319. 
  14. ↑ "Cytoprotective gastric pentadecapeptide BPC 157 resolves major vessel occlusion disturbances, ischemia-reperfusion injury following Pringle maneuver, and Budd-Chiari syndrome". World Journal of Gastroenterology 28 (1): 23–46. January 2022. doi:10.3748/wjg.v28.i1.23. PMID 35139112. 
  15. ↑ "Stable Gastric Pentadecapeptide BPC 157 Therapy of Rat Glaucoma". Biomedicines 10 (1): 89. December 2021. doi:10.3390/biomedicines10010089. PMID 35010781. 
  16. ↑ 16.0 16.1 "Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review". HSS Journal 21 (4). 2025. doi:10.1177/15563316251355551. PMID 40756949. 
  17. ↑ "Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats". Journal of Orthopaedic Surgery and Research 14 (1). July 2019. doi:10.1186/s13018-019-1242-6. PMID 31355337. 
  18. ↑ Sehgal, Priyanka; Gupta, Ritu; Choudhary, Kriti; Singh, Rashmi (2025). "BPC 157: A Promising Candidate for Cytoprotection and Tissue Repair". Pharmaceuticals (MDPI) 18 (2): 185. doi:10.3390/ph18020185. ISSN 1424-8247. PMID 40005999. 
  19. ↑ "2022 Prohibited List: SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)". WADA. https://www.wada-ama.org/sites/default/files/2022-01/2022list_draft_explanatory_list_en_0.pdf. 
  20. ↑ "WORLD ANTI-DOPING CODE INTERNATIONAL STANDARD PROHIBITED LIST 2025". WADA. https://www.wada-ama.org/sites/default/files/2024-09/2025list_en_final_clean_12_september_2024.pdf. 
  21. ↑ "Injectable Therapeutic Peptides—An Adjunct to Regenerative Medicine and Sports Performance?". Arthroscopy 41 (2): 150–152. 2025. doi:10.1016/j.arthro.2024.09.005. PMID 39265666. 
  22. ↑ "Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review". Pharmaceuticals 18 (2): 185. 2025. doi:10.3390/ph18020185. PMID 40005999. 
  23. ↑ "Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing". Current Reviews in Musculoskeletal Medicine 18 (12): 611–619. 2025. doi:10.1007/s12178-025-09990-7. PMID 40789979. 
  24. ↑ "Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds". Regulatory Toxicology and Pharmacology 114. 2020. doi:10.1016/j.yrtph.2020.104665. PMID 32334036. 
  25. ↑ "Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain". Alternative Therapies in Health and Medicine 27 (4): 8–13. 2021. PMID 34324435. 
  26. ↑ "Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study". Alternative Therapies in Health and Medicine 30 (10): 12–17. 2024. PMID 39325560. 
  27. ↑ Notice of interim decisions to amend (or not amend) the current Poisons Standard. Therapeutic Goods Administration, 3 April 2024
  28. ↑ Classification of Unscheduled Peptides. Submission to the Medicines Classification Committee. Medsafe, June 2025
  29. ↑ Cox, Holly D.; Miller, Geoff D.; Eichner, Daniel (2017). "Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H". Drug Testing and Analysis 9 (10): 1490–1498. doi:10.1002/dta.2152. ISSN 1942-7603. PMID 28035768. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:BPC-157&oldid=4309932"